{"denoms":[{"counts":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"100"}],"units":"Participants"}],"groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"BG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"BG001","title":"Methotrexate (Group B)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.60","value":"49.7"},{"groupId":"BG001","spread":"10.51","value":"49.7"},{"groupId":"BG002","spread":"9.85","value":"49.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"76"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety population: All patients who received any amount of rituximab or any vaccine."}